FibroBiologics ships third CYWC628 batch to Australia for Phase 1/2 diabetic foot ulcer trial - FBLG News | RalliesFibroBiologics ships third CYWC628 batch to Australia for Phase 1/2 diabetic foot ulcer trial
F
FBLG• Third batch supports ongoing Australian dosing
- FibroBiologics released a third batch of CYWC628 for its Phase 1/2 diabetic foot ulcer trial, supporting continued dosing at Australian sites.
- CYWC628 is a topical allogeneic fibroblast cell therapy being tested alongside standard care versus standard care alone.
- Results have not been presented; statistically significant interim primary outcome data are expected in the second half of 2026.
- Early progress in the ongoing study was described as encouraging, pointing to potential clinical benefit if confirmed in interim readouts.
FAMI
•
